Infectious Disease Therapy
Novel thiacetazone derivative highly active against Mycobacterium avium
Published in Drug Week, September 26th, 2003
"In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 microg/mL or lower," according to L.E. Bermudez and colleagues at Oregon State University.
"In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens," they reported.
"A combination of SRI-286 and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2003-09-26)
More Articles from Drug Week
- Compound Librarires
New compound library to speed drug discovery - Pain Medicine
Vioxx relieves acute pain following bunion surgery - Cancer Research
Gene needed for antibody-producing cell development is key to blood cell cancer - Infectious Disease Therapy
Novel carbapenems show promise for treatment of drug-resistant pathogens - Liver Cancer
Increased heparanase levels are involved in hepatocellular carcinoma pathology - Pharmacokinetics
Sampling timing and washout interval effects on drug carryover reported - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
